Latest & greatest articles for sitagliptin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sitagliptin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sitagliptin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sitagliptin

21. JANUVIA 50 mg and XELEVIA 50 mg (sitagliptin), DPP-4 inhibitor

JANUVIA 50 mg and XELEVIA 50 mg (sitagliptin), DPP-4 inhibitor JANUVIA XELEVIA SUMMARY CT12571 CT12572

Haute Autorite de sante2016

22. Dynamic Change of Focal Fatty Sparing in Non-Alcoholic Fatty Liver Disease after Treatment with Sitagliptin

Dynamic Change of Focal Fatty Sparing in Non-Alcoholic Fatty Liver Disease after Treatment with Sitagliptin 27689184 2016 10 05 2016 12 30 2509-596X 2 3 2016 Sep Ultrasound international open Ultrasound Int Open Dynamic Change of Focal Fatty Sparing in Non-Alcoholic Fatty Liver Disease after Treatment with Sitagliptin. E98-9 10.1055/s-0036-1582302 Hoffmanová I I Škrha P P Šedo A A Anděl M M eng Journal Article 2016 06 07 Germany Ultrasound Int Open 101674542 2199-7152 2016 10 1 6 0 2016 10 1 6

Ultrasound international open2016 Full Text: Link to full Text with Trip Pro

23. Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin

Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin 27160639 2016 07 13 2017 02 20 1463-1326 18 8 2016 Aug Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. 812-9 10.1111/dom.12684 To evaluate the efficacy and safety of titrated canagliflozin, a sodium glucose co (...) -transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and sitagliptin. In this randomized, double-blind study, patients with T2DM (N = 218) on metformin ≥1500 mg/day and sitagliptin 100 mg received canagliflozin 100 mg or placebo. After 6 weeks, the canagliflozin dose was increased from 100 to 300 mg (or from placebo to matching placebo) if all of the following criteria were met: baseline estimated glomerular filtration rate ≥70 ml/min/1.73 m(2

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

24. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomised, active comparator clinical trial

Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomised, active comparator clinical trial 27060930 2016 07 13 2017 02 20 1463-1326 18 8 2016 Aug Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator (...) clinical trial. 803-11 10.1111/dom.12674 To compare the efficacy and safety of liraglutide versus sitagliptin as add-on to metformin after 26 weeks of treatment in Chinese patients with type 2 diabetes mellitus (T2DM). This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

25. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.

Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study. BACKGROUND: Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents. OBJECTIVE: To examine the associations of hHF with saxagliptin and sitagliptin. DESIGN: Population (...) -based, retrospective, new-user cohort study. SETTING: 18 health insurance and health system data partners in the U.S. Food and Drug Administration's Mini-Sentinel program. PATIENTS: Patients aged 18 years or older with type 2 diabetes who initiated therapy with saxagliptin, sitagliptin, pioglitazone, second-generation sulfonylureas, or long-acting insulin products from 2006 to 2013. MEASUREMENTS: Hospitalized HF, identified by International Classification of Diseases, Ninth Revision, Clinical

Annals of Internal Medicine2016 Full Text: Link to full Text with Trip Pro

26. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.

Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26672857 Format MeSH and Other Data E-mail (...) Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Dec 17;373(25):2479. doi: 10.1056/NEJMc1510995. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. , . Comment on [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] PMID: 26672857 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substances Full Text

NEJM2015

27. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.

Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26672858 Format MeSH and Other Data E-mail (...) Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Dec 17;373(25):2478. doi: 10.1056/NEJMc1510995#SA1. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. , , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26672858 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments

NEJM2015 Full Text: Link to full Text with Trip Pro

28. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.

Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26672859 Format MeSH and Other Data E-mail (...) Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Dec 17;373(25):2478. doi: 10.1056/NEJMc1510995#SA2. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26672859 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How

NEJM2015 Full Text: Link to full Text with Trip Pro

29. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.

Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26672860 Format MeSH and Other Data E-mail (...) Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Dec 17;373(25):2479. doi: 10.1056/NEJMc1510995#SA3. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26672860 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How

NEJM2015 Full Text: Link to full Text with Trip Pro

31. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26182233 Format MeSH (...) and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Aug 6;373(6):586. doi: 10.1056/NEJMx150029. Epub 2015 Jul 16. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. [No authors listed] Erratum for [N Engl J Med. 2015] PMID: 26182233 DOI: Free full text Publication type Full Text Sources PubMed Commons 0 comments How to cite

NEJM2015

32. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed (...) at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference

NEJM2015

33. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5) 24742660 2014 07 25 2015 09 29 2016 12 15 1935-5548 37 8 2014 Aug Diabetes care Diabetes Care Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). 2149-58 10.2337/dc13-2761 To compare the efficacy and safety of two doses of once-weekly dulaglutide, a glucagon-like peptide 1 receptor (...) agonist, to sitagliptin in uncontrolled, metformin-treated patients with type 2 diabetes. The primary objective was to compare (for noninferiority and then superiority) dulaglutide 1.5 mg versus sitagliptin in change from baseline in glycosylated hemoglobin A1c (HbA1c) at 52 weeks. This multicenter, adaptive, double-blind, parallel-arm study randomized patients (N = 1,098; mean baseline age 54 years; HbA1c 8.1% [65 mmol/mol]; weight 86.4 kg; diabetes duration 7 years) to dulaglutide 1.5 mg

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

34. Sitagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Sitagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment) Sitagliptin – nutzenbewertung gemäß § 35a SGB V [Sitagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Sitagliptin – nutzenbewertung gemäß § 35a SGB V [Sitagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Sitagliptin – nutzenbewertung gemäß § 35a SGB V. [Sitagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 175. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus, Type 2s; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents

Health Technology Assessment (HTA) Database.2014

35. Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment) Sitagliptin/metformin – nutzenbewertung gemäß § 35a SGB V [Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Sitagliptin/metformin – nutzenbewertung gemäß § 35a SGB V [Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Sitagliptin/metformin – nutzenbewertung gemäß § 35a SGB V. [Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 176. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes

Health Technology Assessment (HTA) Database.2014

36. Addendum to commission A13-03 (sitagliptin/metformin)

Addendum to commission A13-03 (sitagliptin/metformin) Addendum zum auftrag A13-03 (sitagliptin/metformin) [Addendum to commission A13-03 (sitagliptin/metformin)] Addendum zum auftrag A13-03 (sitagliptin/metformin) [Addendum to commission A13-03 (sitagliptin/metformin)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Addendum (...) zum auftrag A13-03 (sitagliptin/metformin). [Addendum to commission A13-03 (sitagliptin/metformin)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 187. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus, Type 2; Hypoglycemic Agents; Metformins; Pyrazines; Triazoles Language Published German Country of organisation Germany English summary There is no English language summary available. Address

Health Technology Assessment (HTA) Database.2014

37. Sitagliptin in the treatment of type 2 diabetes: a meta-analysis

Sitagliptin in the treatment of type 2 diabetes: a meta-analysis Sitagliptin in the treatment of type 2 diabetes: a meta-analysis Sitagliptin in the treatment of type 2 diabetes: a meta-analysis Zhan M, Xu T, Wu F, Tang Y CRD summary The review found that sitagliptin was efficacious and well tolerated in the treatment of adults with type 2 diabetes compared to placebo. Possibilities of publication and language biases and the inclusion of many trials with an unclear risk of bias mean (...) that the reliability of the review is uncertain. Authors' objectives To assess the efficacy and safety of sitagliptin in adults with type 2 diabetes. Searching MEDLINE, EMBASE and The Cochrane Library were searched to 24 March 2010 for published studies. The search included articles in English; it was unclear whether trials published in Chinese were also eligible. The search strategy was reported. Bibliographies of primary studies and review articles were searched by hand. Abstracts were excluded. Study selection

DARE.2013

38. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study

Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study 22443183 2012 07 27 2012 10 30 2016 10 25 1463-1326 14 9 2012 Sep Diabetes, obesity & metabolism Diabetes Obes Metab Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. 795-802 10.1111/j.1463-1326.2012.01600.x Individuals requiring insulin therapy (...) for type 2 diabetes often require escalation of their regimen to achieve glycaemic control. Optimal management strategies for uncontrolled type 2 diabetes would improve glycaemic control without hypoglycaemia and weight gain. This study compared the efficacy and tolerability of adding sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, and an up to 20% increase in insulin dose in patients with uncontrolled type 2 diabetes on insulin therapy. We conducted a 24-week, randomized, active-competitor, parallel-group

EvidenceUpdates2013

39. Addendum to Commission A13-03 (sitagliptin/metformin)

Addendum to Commission A13-03 (sitagliptin/metformin) 1 Translation of the document “Addendum zum Auftrag A13-03 (Sitagliptin/Metformin)” (Version 1.0; Status: 29 August 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum to Commission A13-03 (sitagliptin/metformin) 1 Addendum IQWiG Reports – Commission No. A13-29 Commission: Version: Status: A13-29 (...) 1.0 29 August 2013 Addendum to Commission A13-03 Version 1.0 (sitagliptin/metformin) 29 August 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic: Addendum to Commission A13-03 (sitagliptin/metformin) Commissioning agency: Federal Joint Committee Commission awarded on: 6 August 2013 Internal Commission No.: A13-29 Address of publisher: Institute for Quality and Efficiency in Health Care Im

Institute for Quality and Efficiency in Healthcare (IQWiG)2013

40. Sitagliptin/metformin - Benefit assessment according to § 35a Social Code Book V

Sitagliptin/metformin - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment “Sitagliptin/Metformin – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status: 27 June 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A13-03 Sitagliptin/metformin (...) – Benefit assessment according to § 35a Social Code Book V 1 Extract of dossier assessment A13-03 Version 1.0 Sitagliptin/metformin – Benefit assessment acc. to § 35a Social Code Book V 27 June 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sitagliptin/metformin – Benefit assessment according to § 35a Social Code Book V Contracting agency: Federal Joint Committee Commission awarded on: 27

Institute for Quality and Efficiency in Healthcare (IQWiG)2013